|
US5164410A
(en)
|
1988-01-09 |
1992-11-17 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
PH26256A
(en)
|
1988-08-12 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
Oxaspiro [2,5] octane derivative
|
|
US5166172A
(en)
|
1988-09-01 |
1992-11-24 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
ATE150750T1
(de)
|
1988-09-01 |
1997-04-15 |
Takeda Chemical Industries Ltd |
Fumagillol-derivate
|
|
US5180738A
(en)
|
1988-09-01 |
1993-01-19 |
Takeda Chemical Industries |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
US5288722A
(en)
|
1989-03-06 |
1994-02-22 |
Takeda Chemical Industries, Ltd. |
6-amino-6-desoxyfumagillols, production and use thereof
|
|
DE69001187T2
(de)
|
1989-03-06 |
1993-07-08 |
Takeda Chemical Industries Ltd |
6-epifumagillole, ihre herstellung und ihre verwendung.
|
|
US6017954A
(en)
|
1989-08-10 |
2000-01-25 |
Children's Medical Center Corp. |
Method of treating tumors using O-substituted fumagillol derivatives
|
|
US5290807A
(en)
|
1989-08-10 |
1994-03-01 |
Children's Medical Center Corporation |
Method for regressing angiogenesis using o-substituted fumagillol derivatives
|
|
EP0415294A3
(en)
|
1989-08-31 |
1991-06-12 |
Takeda Chemical Industries, Ltd. |
Cyclohexanol derivatives, production and use thereof
|
|
TW282399B
(enExample)
|
1990-05-25 |
1996-08-01 |
Takeda Pharm Industry Co Ltd |
|
|
US5238950A
(en)
|
1991-12-17 |
1993-08-24 |
Schering Corporation |
Inhibitors of platelet-derived growth factor
|
|
EP0555693B1
(en)
|
1992-01-30 |
2001-09-05 |
Takeda Chemical Industries, Ltd. |
Method of producing highly watersoluble cyclodextrin complex
|
|
ATE153854T1
(de)
|
1992-12-16 |
1997-06-15 |
Takeda Chemical Industries Ltd |
Stabile pharmazeutische zubereitung mit fumagillolderivaten
|
|
SK283883B6
(sk)
|
1995-03-27 |
2004-04-06 |
Sanofi-Synthelabo |
Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok
|
|
WO1997013509A1
(en)
|
1995-10-11 |
1997-04-17 |
Fujisawa Pharmaceutical Co., Ltd. |
Vascular permeation inhibitor
|
|
EP0799616A1
(en)
|
1996-04-01 |
1997-10-08 |
Takeda Chemical Industries, Ltd. |
Oral composition comprising a fumagillol derivative
|
|
AU3968597A
(en)
|
1996-08-02 |
1998-02-25 |
Children's Medical Center Corporation |
Method of regulating the female reproductive system through angiogenesis inhibitors
|
|
US6281245B1
(en)
|
1996-10-28 |
2001-08-28 |
Versicor, Inc. |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
|
JP2002513407A
(ja)
|
1997-03-04 |
2002-05-08 |
モンサント カンパニー |
Ｎ−ヒドロキシ４−スルホニルブタンアミド化合物
|
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
US6207704B1
(en)
|
1997-06-09 |
2001-03-27 |
Massachusetts Institute Of Technology |
Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
|
|
US6306819B1
(en)
|
1997-10-31 |
2001-10-23 |
Massachusetts Institute Of Technology |
Method for regulating size of vascularized normal tissue
|
|
CA2300197A1
(en)
|
1997-12-23 |
1999-07-01 |
Warner-Lambert Company |
Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
|
|
US6242494B1
(en)
|
1998-05-01 |
2001-06-05 |
Abbott Laboratories |
Substituted β-amino acid inhibitors of methionine aminopeptidase-2
|
|
KR100357541B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
5-데메톡시 푸마질롤 유도체 및 그 제조방법
|
|
KR100357542B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
푸마질롤 유도체 및 그 제조방법
|
|
JP2000116337A
(ja)
|
1998-10-09 |
2000-04-25 |
Nippon Shokuhin Kako Co Ltd |
ペットフード
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
WO2000064876A1
(en)
|
1999-04-28 |
2000-11-02 |
Aventis Pharma Deutschland Gmbh |
Tri-aryl acid derivatives as ppar receptor ligands
|
|
CA2379342C
(en)
|
1999-07-15 |
2007-01-02 |
Basf Aktiengesellschaft |
Process for the preparation of 5- and/or 6-substituted-2-hydroxybenzoic acid esters
|
|
JP2003510359A
(ja)
|
1999-10-01 |
2003-03-18 |
スミスクライン・ビーチャム・コーポレイション |
化合物および方法
|
|
US20020002152A1
(en)
|
2000-04-14 |
2002-01-03 |
Craig Richard A. |
Hydrazide and alkoxyamide angiogenesis inhibitors
|
|
US6323228B1
(en)
|
2000-09-15 |
2001-11-27 |
Abbott Laboratories |
3-substituted indole angiogenesis inhibitors
|
|
UY26929A1
(es)
|
2000-09-29 |
2002-04-26 |
Abbott Lab |
Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
|
|
US6548477B1
(en)
|
2000-11-01 |
2003-04-15 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
EP1330447A2
(en)
|
2000-11-01 |
2003-07-30 |
Praecis Pharmaceuticals Incorporated |
Peptides as met-ap2 inhibitors
|
|
EP1399445B9
(en)
|
2000-12-20 |
2010-07-21 |
Bristol-Myers Squibb Company |
Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
|
|
WO2002078699A1
(en)
|
2001-03-29 |
2002-10-10 |
Smithkline Beecham Corporation |
Compounds and methods
|
|
US20020183242A1
(en)
|
2001-04-11 |
2002-12-05 |
Jack Henkin |
Peptide antiangiogenic drugs
|
|
ATE440094T1
(de)
|
2001-09-27 |
2009-09-15 |
Equispharm Co Ltd |
Fumagillolderivate und verfahren zu deren herstellung
|
|
US6803382B2
(en)
|
2001-11-09 |
2004-10-12 |
Galderma Research & Development, S.N.C. |
Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
|
|
US7119120B2
(en)
|
2001-12-26 |
2006-10-10 |
Genzyme Corporation |
Phosphate transport inhibitors
|
|
KR100451485B1
(ko)
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
US6989392B2
(en)
|
2002-06-18 |
2006-01-24 |
Abbott Laboratories |
2-Aminoquinolines as melanin concentrating hormone receptor antagonists
|
|
US7030262B2
(en)
|
2002-08-06 |
2006-04-18 |
Abbott Laboratories |
3-Amino-2-hydroxyalkanoic acids and their prodrugs
|
|
US20040067266A1
(en)
|
2002-10-07 |
2004-04-08 |
Toppo Frank R. |
Weight loss compound
|
|
US20040157836A1
(en)
|
2002-10-08 |
2004-08-12 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040068012A1
(en)
|
2002-10-08 |
2004-04-08 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US7491718B2
(en)
|
2002-10-08 |
2009-02-17 |
Abbott Laboratories |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040204472A1
(en)
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
|
MXPA06001482A
(es)
|
2003-08-08 |
2006-09-04 |
Johnson & Johnson |
Procedimiento para la preparacion de compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida.
|
|
TW200530157A
(en)
|
2003-09-09 |
2005-09-16 |
Japan Tobacco Inc |
Dipeptidyl peptidase iv inhibitor
|
|
BRPI0417323A
(pt)
|
2003-12-22 |
2007-03-27 |
Memory Pharm Corp |
indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
|
|
EP1699812A2
(en)
|
2003-12-29 |
2006-09-13 |
Praecis Pharmaceuticals Inc. |
Inhibitors of methionine aminopeptidase-2 and uses thereof
|
|
KR100552043B1
(ko)
|
2004-02-28 |
2006-02-20 |
주식회사종근당 |
푸마질롤 유도체를 포함하는 비만치료용 조성물
|
|
JP2007537275A
(ja)
|
2004-05-12 |
2007-12-20 |
ケモセントリックス， インコーポレイテッド |
アリールスルホンアミド
|
|
RU2007103178A
(ru)
|
2004-06-30 |
2008-08-10 |
Комбинаторкс, Инкорпорейтед (Us) |
Способы и реагенты для лечения метаболических нарушений
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
KR20070057252A
(ko)
|
2004-09-24 |
2007-06-04 |
얀센 파마슈티카 엔.브이. |
설폰아미드 화합물
|
|
EP1841761A4
(en)
|
2005-01-26 |
2008-10-29 |
Chong Kun Dang Pharm Corp |
Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them
|
|
FR2886855B1
(fr)
|
2005-06-08 |
2009-07-17 |
Agronomique Inst Nat Rech |
Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
|
|
US20070078172A1
(en)
|
2005-06-16 |
2007-04-05 |
Jenrin Discovery |
Mao-b inhibitors useful for treating obesity
|
|
MX2008008320A
(es)
|
2005-12-23 |
2008-09-03 |
Smithkline Beecham Corp |
Inhibidores de azaindol de aurora cinasas.
|
|
US20100234364A1
(en)
|
2006-07-14 |
2010-09-16 |
Arindrajit Basak |
Ccr2 inhibitors and methods of use thereof
|
|
DE102007020492A1
(de)
|
2007-04-30 |
2008-11-06 |
Grünenthal GmbH |
Substituierte Sulfonamid-Derivate
|
|
CA2690244C
(en)
|
2007-06-26 |
2016-08-09 |
Ofra Benny-Ratsaby |
Metap-2 inhibitor polymersomes for therapeutic administration
|
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
|
US8399512B2
(en)
|
2007-11-28 |
2013-03-19 |
Mersana Therapeutics, Inc. |
Biocompatible biodegradable fumagillin analog conjugates
|
|
KR20100114018A
(ko)
|
2007-11-30 |
2010-10-22 |
바이엘 쉐링 파마 악티엔게젤샤프트 |
헤테로아릴-치환된 피페리딘
|
|
CA2731020A1
(en)
|
2008-07-18 |
2010-01-21 |
Zafgen, Inc. |
Use of antiangiogenic fumagillins in the treatment of obesity
|
|
WO2010042163A2
(en)
|
2008-10-06 |
2010-04-15 |
The Johns Hopkins University |
Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
|
|
US8906896B2
(en)
|
2008-10-24 |
2014-12-09 |
Ulrich Bierbach |
Platinum acridine anti-cancer compounds and methods thereof
|
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US20120010290A1
(en)
|
2008-12-04 |
2012-01-12 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US20120010259A1
(en)
|
2008-12-04 |
2012-01-12 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US8642650B2
(en)
*
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
WO2011044506A2
(en)
*
|
2009-10-09 |
2011-04-14 |
Zafgen Corporation |
Sulphone compounds and methods of making and using same
|
|
WO2011085198A1
(en)
|
2010-01-08 |
2011-07-14 |
Zafgen Corporation |
Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
|
|
US20130023513A1
(en)
|
2010-01-12 |
2013-01-24 |
Hughes Thomas E |
Methods and Compositions for Treating Cardiovascular Disorders
|
|
WO2011150338A1
(en)
|
2010-05-27 |
2011-12-01 |
Zafgen Corporation |
Methods of treating obesity
|
|
US20120020647A1
(en)
|
2010-07-21 |
2012-01-26 |
Rovi Technologies Corporation |
Filtering repeated content
|
|
WO2012012642A1
(en)
|
2010-07-22 |
2012-01-26 |
Zafgen Corporation |
Tricyclic compounds and methds of making and using same
|
|
US8428080B2
(en)
|
2010-09-16 |
2013-04-23 |
Apple Inc. |
Method to control reconfiguration of multiple radio access bearers in a wireless device
|
|
AU2011316550A1
(en)
|
2010-10-12 |
2013-05-02 |
Zafgen, Inc |
Sulphonamide compounds and methods of making and using same
|
|
PH12013500934A1
(en)
|
2010-11-09 |
2022-10-24 |
Zafgen Inc |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
|
WO2012064928A1
(en)
|
2010-11-10 |
2012-05-18 |
Zafgen Corporation |
Methods and compositions for treating thyroid hormone related disorders
|
|
WO2012074968A1
(en)
|
2010-11-29 |
2012-06-07 |
Zafgen Corporation |
Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
|
|
KR20140006888A
(ko)
|
2011-01-26 |
2014-01-16 |
자프겐 인크. |
테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
|
|
KR101979039B1
(ko)
*
|
2011-05-06 |
2019-05-15 |
자프겐 인크. |
부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
|
|
US9242997B2
(en)
|
2011-05-06 |
2016-01-26 |
Zafgen, Inc. |
Tricyclic pyrazole sulphonamide compunds and methods of making and using same
|
|
CN103748094B
(zh)
|
2011-05-06 |
2016-06-29 |
扎夫根股份有限公司 |
三环磺酰胺化合物及其制备和使用方法
|
|
WO2013033430A1
(en)
|
2011-09-02 |
2013-03-07 |
Wake Forest School Of Medicine |
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
|
|
AU2013337288A1
(en)
|
2012-11-05 |
2015-05-21 |
Zafgen, Inc. |
Tricyclic compounds for use in the treatment and/or control of obesity
|
|
CA2890342A1
(en)
|
2012-11-05 |
2014-05-08 |
Zafgen, Inc. |
Tricyclic compounds and methods of making and using same
|